J
John Q. Trojanowski
Researcher at University of Pennsylvania
Publications - 1538
Citations - 245534
John Q. Trojanowski is an academic researcher from University of Pennsylvania. The author has contributed to research in topics: Dementia & Alzheimer's disease. The author has an hindex of 226, co-authored 1467 publications receiving 213948 citations. Previous affiliations of John Q. Trojanowski include Vanderbilt University & University of California, San Francisco.
Papers
More filters
Journal ArticleDOI
Recent publications from the Alzheimer's Disease Neuroimaging Initiative: Reviewing progress toward improved AD clinical trials
Michael W. Weiner,Dallas P. Veitch,Paul S. Aisen,Laurel A. Beckett,Nigel J. Cairns,Robert C. Green,Danielle J Harvey,Clifford R. Jack,William J. Jagust,John C. Morris,Ronald C. Petersen,Andrew J. Saykin,Leslie M. Shaw,Arthur W. Toga,John Q. Trojanowski +14 more
TL;DR: In a recent review as discussed by the authors, the Alzheimer's Disease Neuroimaging Initiative (ADNI) has continued development and standardization of methodologies for biomarkers and has provided an increased depth and breadth of data available to qualified researchers.
Journal ArticleDOI
TDP-43 proteinopathy: the neuropathology underlying major forms of sporadic and familial frontotemporal lobar degeneration and motor neuron disease.
TL;DR: This review summarizes the growing evidence that TDP-43 proteinopathy is the common pathologic substrate linking FTLD and ALS, and it considers the implications for developing better strategies to diagnose and treat these neurodegenerative disorders.
Journal ArticleDOI
An R5L τ mutation in a subject with a progressive supranuclear palsy phenotype
Parvoneh Poorkaj,Nancy A. Muma,Victoria Zhukareva,Elizabeth J. Cochran,Kathleen M. Shannon,Howard I. Hurtig,William C. Koller,Thomas D. Bird,Thomas D. Bird,John Q. Trojanowski,Virginia M.-Y. Lee,Gerard D. Schellenberg +11 more
TL;DR: Analysis of soluble tau from different brain regions indicates that the mutation does not affect the ratio of tau isoforms synthesized, and the R5L mutation causes a progressive supranuclear palsy phenotype, presumably by a gain‐of‐function mechanism.
Journal ArticleDOI
Dysregulation of the epigenetic landscape of normal aging in Alzheimer's disease.
Raffaella Nativio,Greg Donahue,Amit Berson,Yemin Lan,Alexandre Amlie-Wolf,Ferit Tuzer,Jon B. Toledo,Sager J. Gosai,Brian D. Gregory,Claudio Torres,John Q. Trojanowski,Li-San Wang,F. Brad Johnson,Nancy M. Bonini,Shelley L. Berger +14 more
TL;DR: By comparing the genome-wide profile of H4K16ac in AD with younger and elder controls, the authors propose a mechanism for how age is a risk factor for AD: a histone modification, whose accumulation is associated with aging, is dysregulated in AD.
Journal ArticleDOI
Guidelines for the standardization of preanalytic variables for blood-based biomarker studies in Alzheimer's disease research
Sid E. O'Bryant,Veer Bala Gupta,Kim Henriksen,Melissa Edwards,Andreas Jeromin,Simone Lista,Chantal Bazenet,Holly Soares,Simon Lovestone,Harald Hampel,Harald Hampel,Harald Hampel,Thomas J. Montine,Kaj Blennow,Tatiana Foroud,Maria C. Carrillo,Neill R. Graff-Radford,Christoph Laske,Monique M.B. Breteler,Monique M.B. Breteler,Leslie M. Shaw,Leslie M. Shaw,John Q. Trojanowski,John Q. Trojanowski,Nicole Schupf,Robert A. Rissman,Anne M. Fagan,Pankaj Oberoi,Robert M. Umek,Michael W. Weiner,Paula Grammas,Holly Posner,Ralph N. Martins +32 more
TL;DR: The lack of readily available biomarkers is a significant hindrance toward progress to effective therapeutic and preventative strategies for Alzheimer's disease (AD) as discussed by the authors, and the current international working group provides the initial starting point for such guidelines for standardized operating procedures.